SPYR Inc (OTCMKTS:SPYR) has launched its new corporate website to run and showcase all the offerings in a hassle-free way. SPYR Inc is better known for owning a major stake in a wide range of companies in advertising, digital media, app development and mobile game development field. The new website, www.spyr.com, has been designed with the help of COHN Inc., an award-winning marketing agency of SPYR Inc.
It will now become easier for advertisers, investors and public to find relevant information about SPYR Inc’s stock, corporate affairs, subsidiaries, etc. at one place. The entire senior management team including company’s CEO James R. Thompson is delighted to have this new site in place and hope that it will serve company’s purpose in an effective way.
Marchex, Inc. (NASDAQ:MCHX) Announces $35.3 Million GAAP Revenue in 2Q2015
Marchex, Inc. (NASDAQ:MCHX) has reported financial results for the recently concluded 2Q2015. The company could manage $35.3 million GAAP revenue as compared to $47 million in 2Q2014. Among others, the sale of GoDaddy Inc. marked a major transaction in the quarter and subsequently earned a massive $28.1 million to Marchex. Apart from this, Marchex also generated call-driven revenues of $34.5 million. During the same three-month period, Marchex got into a strategic partnership with Light Reaction to float a click-to-call mobile platform called M-Call.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Acquires Sprout Pharma For $1 Billion
To enhance its product portfolio and expertise, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has acquired Sprout Pharma for as much as $1 billion. Sprout Pharma’s viagra for women has recently been given approval by U.S. FDA. Now, it can be used to treat hypoactive sexual desire in women. Reports claim that the drug will officially be launched in 4Q2015 due to certain formalities. As soon as the paperwork finishes, Cindy Whitehead, CEO of Sprout will start reporting to Anne Whitaker, Group Chairman & EVP, Valeant Pharmaceuticals.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: